Genmab — December 2024
-
Genmab får hævet anbefaling til "market perform" af Bernstein https://proinvestor.com/investornyt/1256245/genmab-far-haevet-anbefaling-til-market-perform-af-bernstein
-
Japanese GEN1042 trial adds 2 arms , but i can not immediately see the difference between cohorts 1&2 and 3&4... https://clinicaltrials.gov/study/NCT06057038?tab=history&a=13&b=14&compareMode=sideBySide#version-content-panel
-
-
Tjaa
-
Det er lang tid siden man som aktionær i Genmab har haft en følelse af “outstanding year”
-
Medarbejdere der er ansat de seneste 5 år, ligger også inde med en stak værdiløse warrants. De har nok også svært ved at se Hvad der er outstanding!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
